Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06936332 · ClinicalTrials.gov registry record · NA

Study Evaluating the Efficacy and Safety of Omnilux Clear on Mitigating Mild to Moderate Acne

A NA study, sponsored by Ablon Skin Institute Research Center.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT06936332 is a NA study that has completed, run by Ablon Skin Institute Research Center. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06936332, a NA study, has completed, sponsored by Ablon Skin Institute Research Center.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

The goal of this clinical trial is to further substantiate the effectiveness and safety of Omnilux Clear as a stand-alone treatment of mild to moderate acne in healthy teenagers and adults 14 years of age or older over the course of 7 weeks. Participants will be screened to determine eligibility, assessed, instructed on how to use the Omnilux Clear and then treated with Omnilux Clear under the direction of the study staff during the first office visit. The first treatment will also act as a photosensitivity "patch" test to evaluate the participant for any unknown hereditary photosensitivity conditions or allergies to surface contacting materials. The particpants will then treat their face with the Omnilux Clear device at home 4 times per week for the first 6 weeks of the trial. The treatments are 10 minutes in duration. Participants will return to the study site at week 3 and week 7 for assessments, photographs and questionnaires.

Interventions

  • DEVICE Omnilux Clear Light Emitting Diode Treatment

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2024-11-18
Est. Completion 2025-04-10
Phase NA

What the Registry Record Tells You About NCT06936332

The ClinicalTrials.gov registry entry for NCT06936332 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ablon Skin Institute Research Center, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Omnilux Clear Light Emitting Diode Treatment is the first listed.

NCT06936332 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06936332 about?

NCT06936332 is a clinical study titled "Study Evaluating the Efficacy and Safety of Omnilux Clear on Mitigating Mild to Moderate Acne". The goal of this clinical trial is to further substantiate the effectiveness and safety of Omnilux Clear as a stand-alone treatment of mild to moderate acne in healthy teenagers and adults 14 years of age or older over the course of 7 weeks. Participants will be screened to determine eligibility, as...

What is the current status of trial NCT06936332?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2024-11-18. Estimated completion is 2025-04-10.

What interventions are being tested in trial NCT06936332?

The interventions under investigation include: Omnilux Clear Light Emitting Diode Treatment (DEVICE).

Who is sponsoring clinical trial NCT06936332?

This trial is sponsored by Ablon Skin Institute Research Center, which has 7 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.